These findings reveal the importance of anti-PD1 immunotherapy not only for disruption of the PD1 signaling cascade, but also the ability of this inhibition to prime the immune system to response robustly to highly mutagenic cancers that may be expressing neoantigens. This evidence concerns the gene PDCD1 and cancer.